Theriva Biologics (TOVX) Long-Term Debt Issuances (2025)
Theriva Biologics (TOVX) posted quarterly Long-Term Debt Issuances of $15000.0 for Q4 2025, down 55.88% quarter-over-quarter from $34000.0 in Q3 2025.
Theriva Biologics (TOVX) Long-Term Debt Issuances (2025) Analysis & Trends
Theriva Biologics (TOVX) has reported Long-Term Debt Issuances for 1 consecutive years, with $15000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Long-Term Debt Issuances changed N/A year-over-year to $15000.0; the TTM figure through Dec 2025 stood at $1.5 million (changed N/A YoY), while the FY2025 annual figure was $1.5 million, changed N/A from the prior year.
- Long-Term Debt Issuances slipped to $15000.0 in Q4 2025 per TOVX's latest filing, from $34000.0 in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $1.4 million in Q1 2025 and bottomed at $15000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Theriva Biologics | 10.64 Mn | 10.64 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 15,000.00 |
| Dec 31, 2025 | 15,000.00 |
| Sep 30, 2025 | 34,000.00 |
| Sep 30, 2025 | 34,000.00 |
| Jun 30, 2025 | 57,000.00 |
| Jun 30, 2025 | 57,000.00 |
| Mar 31, 2025 | 1.40 Mn |
| Mar 31, 2025 | 1.40 Mn |